Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- SAIC +7.6%, CI +0.4% (reaffirms FY23 EPS guidance)
Other news:
- EYPT +382.6% (announced positive topline results of its Phase 2 DAVIO 2 trial of EYP-1901)
- ATHE +375.3% (announced that promising new data on the effect of ATH434 in a Parkinson's disease primate model was presented at the Future of Parkinson's Disease Conference 2023)
- HA +184.6% (Hawaiian Holdings to be acquired by Alaska Air (ALK) for $18.00 per share)
- CIFR +10.5% (Announces November 2023 Operational Update)
- ETNB +6.4% (announces a successful end-of-Phase 2 Meeting with the U.S. FDA, supporting the advancement of pegozafermin into Phase 3 in NASH)
- RDHL +6.1% (new, non-dilutive external funding of entire RHB-107 COVID-19 300-patient phase 2 study)
- GERN +5.5% (Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS)
- APXI +5% (APX Acquisition Corp. I and Bioceres Group announce Letter of Intent for a business combination)
- XENE +3.6% (Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society)
- ATLX +2.9% (entered into two securities purchase agreements dated November 29, 2023)
- NSA +2.7% (approves a new share repurchase program authorizing the repurchase of up to $275 mln)
- MRUS +2.7% (Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023)
- SPOT +2.6% (to reduce its total headcount by approximately 17% across the company)
- SANA +2.2% (publishes early clinical data showing that SC291, a CD19-directed Allogeneic CAR T Therapy, evades immune detection in presence of intact immune system)
- ERIC +1.8% (speculation from industry analyst that AT&T (T) might remove Nokia from its list of 5G equipment suppliers; may be positive for ERIC)
- IDYA +1.2% (announces clinical study collaboration with Gilead Sciences (GILD) to evaluate Trodelvy and IDE397 combination)
- GDHG +1.2% (announces strategic initiatives) .
Analyst comments:
- CVNA +5.3% (upgraded to Neutral from Underweight at JP Morgan)
- FLNC +2.6% (upgraded to Buy from Neutral at ROTH MKM)
- CCEP +1.7% (upgraded to Buy from Neutral at Goldman)
- CYBR +1.5% (upgraded to Overweight from Equal Weight at Wells Fargo)
- CNX +1.3% (upgraded to Buy from Hold at Truist)
- GM +1.3% (upgraded to Buy from Neutral at Mizuho)